Exploiting information inherent in binding sites of virus-specific antibodies: Design of an HCV vaccine candidate cross-reactive with multiple genotypes

Antiviral Therapy

Volumn 11, Issue 8, 2006, Pages 1005-1014

  Grollo, Lam ^a   Torresi, Joseph ^a   Drummer, Heidi ^b   Zeng, Weiguang ^a   Williamson, Nicholas ^a   Jackson, David C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS ANTIBODY; HEPATITIS C VACCINE; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; PEPTIDE LIBRARY; PROTEIN P113; PROTEIN P122; PROTEIN P125; PROTEIN P79; PROTEIN P90; SARALASIN; SYNTHETIC PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BINDING SITE; CONTROLLED STUDY; CONVALESCENCE; CROSS REACTION; DRUG DESIGN; FEMALE; GENOTYPE; HELPER CELL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; VIRION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CELL LINE; CROSS REACTIONS; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MICE; MICE, INBRED BALB C; PEPTIDE LIBRARY; VIRAL HEPATITIS VACCINES; VIRAL PROTEINS;

EID: 33845666631     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine 1999; 17:1730-1733.
2. Hadziyannis SJ, Sette H, Jr, Morgan TR, et al, Peginterferon-alphala and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
3. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197:633-642.
4. Farci P, Alter HJ, Wong DC, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994; 91:7792-7796.
5. Ward S, Lauer G, Isba R, Walker B, Klenerman P. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol 2002; 128:195-203.
6. Bichr S, Rende-Fournier R, Vona G, et al. Detection of neutralizing antibodies to hepatitis C virus using a biliary cell infection model. J Gen Virol 2002; 83:1673-1678.
7. Farci P, Shimoda A, Wong D, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 1996; 93:15394-15399.
8. Rosa D, Campagnoli S, Moretto C, et al. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci USA 1996; 93:1759-1763.
9. Shimizu YK, Igarashi H, Kiyohara T, et al. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology 1996; 223:409-412.
10. Zibert A, Meisel H, Kraas W, Schulz A, Jung G, Roggendorf M. Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. Hepatology 1997; 25:1245-1249.
11. Yu MY, Bartosch B, Zhang P, et al. Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci USA 2004; 101:7705-7710.
12. Beignon AS, Brown F, Eftekhari P, et al. A peptide vaccine administered transcutaneously together with cholera toxin elicits potent neutralising anti-FMDV antibody responses. Vet Immunol Immunopathol 2005; 104:273-280.
13. Deliyannis G, Jackson DC, Ede NJ, et al. Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. J Virol 2002; 76:4212-4221.
14. Deliyannis G, Kedzierska K, Lau YF, et al. Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. Eur J Immunol 2006; 36:770-778.
15. Dong XN, Wei K, Liu ZQ, Chen YH. Candidate peptide vaccine induced protection against classical swine fever virus. Vaccine 2002; 21:167-173.
16. Embers ME, Budgeon LR, Pickel M, Christensen ND. Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol 2002; 76:9798-9805.
17. Jackson DC, Lau YF, Le T, et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci USA 2004; 101:15440-15445.
18. Hsu M, Zhang J, Flint M, et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 2003; 100:7271-7276.
19. Tarr AW, Owsianka AM, Timms JM, et al. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 2006; 43:592-601.
20. Eren R, Landstein D, Terkieltaub D, et al. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol 2006; 80:2654-2664.
21. Drummer HE, Maerz A, Poumbourios P. Cell surface expression of functional hepatitis C virus El and E2 glycoproteins. FEBS Lett 2003; 546:385-390.
22. Zeng W, Ghosh S, Lau YF, Brown LE, Jackson DC. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol 2002; 169:4905-4912.
23. Ghosh S, Walker J, Jackson DC. Identification of canine helper T-cell epitopes from the fusion protein of canine distemper virus. Immunology 2001; 104:58-66.
24. Zeng W, Ghosh S, Macris M, Pagnon J, Jackson DC. Assembly of synthetic peptide vaccines by chemoselective ligation of epitopes: influence of different chemical linkages and epitope orientations on biological activity. Vaccine 2001; 19:3843-3852.
25. Brown LE, Ffrench RA, Gawler JM, et al. Distinct epitopes recognized by I-Ad-restricted T-cell clones within antigenic site E on influenza virus hemagglutinin. J Virol 1988; 62:305-312.
26. He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting P34cdc2 activity. J Virol 1995; 69:6705-6711.
27. NCBI database. Available from: www.ncbi.nlm.nih.gov.
28. HCV sequence database. Available from: http://hcv.lanl.gov/content/hcv- db/classification/ genotable.html.
29. Cerino A, Meola A, Segagni L, et al. Monoclonal antibodies with broad specificity for hepatitis C virus hypervariable region 1 variants can recognize viral particles. J Immunol 2001; 167:3878-3886.
30. Mondelli MU, Cerino A, Segagni L, et al. Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain? Antiviral Res 2001; 52:153-159.
31. Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH, Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 1994; 68:1494-1500.
32. Drummer HE, Poumbourios P. Hepatitis C virus glycoprotein E2 contains a membrane-proximal heptad repeat sequence that is essential for E1E2 glycoprotein heterodimerization and viral entry. J Biol Chem 2004; 279:30066-30072.
33. Flint M, Maidens C, Loomis-Price LD, et al. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol 1999; 73:6235-6244.
34. Keck ZY, Op De Beeck A, Hadlock KG, et al. Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J Virol 2004; 78:9224-9232.
35. Lee JW, Kim K, Jung SH, et al. Identification of a domain containing B-cell epitopes in hepatitis C virus E2 glycoprotein by using mouse monoclonal antibodies. J Virol 1999; 73:11-18.
36. Zibert A, Kraas W, Ross RS, et al. Immunodominant B-cell domains of hepatitis C virus envelope proteins El and E2 identified during early and late time points of infection. J Hepatol 1999; 30:177-184.
37. Hadlock KG, Lanford RE, Perkins S, et al. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol 2000; 74:10407-10416.
38. Keck ZY, Sung VM, Perkins S, et al. Human monoclonal antibody to hepatitis C virus El glycoprotein that blocks virus attachment and viral infectivity. J Virol 2004; 78:7257-7263.
39. Lechner S, Rispeter K, Meisel H, et al. Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1. Virology 1998; 243:313-321.
40. Sobolev BN, Poroikov, W, Olenina, LV, Kolesanova EF, Archakov AI. Comparative analysis of amino acid sequences from envelope proteins isolated from different hepatitis C virus variants: possible role of conservation and variable regions. J Viral Hep 2000; 7:368-374.
41. Schoofs PG, Geysen HM, Jackson DC, Brown LE, Tang XL, White DO. Epitopes of an influenza viral peptide recognized by antibody at single amino acid resolution. J Immunol 1988; 140:611-616.
42. Yu M, Zeng W, Pagnon J, et al. Identification of dominant epitopes of synthetic immunocontraceptive vaccines that induce antibodies in dogs. Vaccine 2005; 23:4589-4597.
43. Steinmann D, Earth H, Gissler B, et al. Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol 2004; 78:9030-9040.
44. Roccasecca R, Ansuini H, Vitelli A, et al. Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J Virol 2003; 77:1856-1867.
45. Drummer HE, Boo I, Maerz AL, Poumbourios P. A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry. J Virol 2006; 80:7844-7853.